Joshua Phillipson

Investor Relations, Marketing, Communications and Business Development for Pharma and Biotechs. Proud 🇨🇦&🇮🇱. Personal account.

[Joshua Phillipson @BioJEP]

To the guy who said to me last year:

“What’s the big deal with rebranding? Just use some free online AI to choose a name and create a logo!”

Here’s (part of) the answer: https://t.co/tg4XY8aOj6

#Rebranding #Communications #InvestorRelations #Strategy #Marketing

[Scinai Immunotherapeutics Ltd @scinai]

Meet us next week at #BIOEuropeSpring in Barcelona!

Email [email protected] to schedule a meeting, or visit Booth #119

[Scinai Immunotherapeutics Ltd @scinai]

Scinai will host an analyst and investors webinar on January 9th.

Space is limited. REGISTER NOW https://t.co/JWm2dHkwUJ

$SCNI

[Scinai Immunotherapeutics Ltd @scinai]

Study published this week in #AntiviralResearch supports the exciting promise of our NanoAbs

> https://t.co/jQEOwW7HuC

$SCNI

[Joshua Phillipson @BioJEP]

Great step forward

[Scinai Immunotherapeutics Ltd @scinai]

We're very pleased to announce promising results for our anti-IL-17 NanoAb as an innovative psoriasis treatment

Details here > https://t.co/EPp0Mq5gdM

$SCNI #psoriasis #nanobody #antibody #NanoAb #treatment

[Cision/PR Newswire Israel @PRNewswireIL]

#Study #published in #Antiviral #Research #supports #promise of #Scinai #Immunotherapeutics' #coronavirus #NanoAb as #aerosolized #prophylactic and #therapeutic #drug https://t.co/wgnmrVvT8f $SCNI @Scinai_

[Scinai Immunotherapeutics Ltd @scinai]

Thank you to Ohad Lavi, CEO of Voyager Medical Research, for choosing Scinai Bioservices as your CDMO!
https://t.co/FtcskVx5Gq

Limited availability for 2024 - Contact [email protected] for info today!

[Scinai Immunotherapeutics Ltd @scinai]

Good news! Thanks to @InnovationAut for their support and belief in Scinai's exciting potential!

The IAA approved a grant covering 66% of a ₪3.5m (~US$900K) project for our new CDMO business unit.

Details > https://t.co/PQbU6byUFC

$SCNI #CDMO #IsraelInnovation 🇮🇱

[Scinai Immunotherapeutics Ltd @scinai]

Scinai’s #CDMO offers upstream and downstream process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing including aseptic filling to biopharmaceutical and biotech clients.

Meet us @CPHI_Events via [email protected]

[Scinai Immunotherapeutics Ltd @scinai]

We're excited to share today encouraging results in a preclinical study of our anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.

https://t.co/gHnHuqWdx1

$SCNI #NanoAb #Psoriasis #Scinai #Immunotherapeutics

[Joshua Phillipson @BioJEP]

https://t.co/FuBPr7d3eq

[Joshua Phillipson @BioJEP]

Grateful his music lives on
https://t.co/aq5SuwOLvh

[Joshua Phillipson @BioJEP]

https://t.co/0BqM3znQ5r

[Joshua Phillipson @BioJEP]

Great to see $GMDA's FDA approval today! Congrats @GamidaCellTx

[Joshua Phillipson @BioJEP]

@AriZoldan @Nasdaq Great to meet you last week in Basel, Ari. And thanks for including @BiondVax's story in your summary of the conference: https://t.co/6MnzKAjeZj

[Scinai Immunotherapeutics Ltd @scinai]

Meet @ReichmanAmir, BiondVax's CEO, on the 101st episode of the popular Test.Optimize.Scale podcast.

> @YouTube https://t.co/FhJSg4YKeW
> @Spotify https://t.co/ZHy3g9v4xY
and other popular podcast platforms.

#BiondVax $BVXV #Leadership #vision #innovation

[Scinai Immunotherapeutics Ltd @scinai]

[EXCITING NEW RESULTS] COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2

Details > https://t.co/hPskNXM8iK

#COVID19 #Protection #Prophylactic $BVXV #BVXV

[Scinai Immunotherapeutics Ltd @scinai]

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

https://t.co/eG1YwqaHuZ

$BVXV #BiondVax

[Joshua Phillipson @BioJEP]

We keep #GoodCompany

[Scinai Immunotherapeutics Ltd @scinai]

@maxplanckpress @MPI_EVA_Leipzig Congrats @maxplanckpress for your 3rd Nobel Prize in the past 2 years!
The awards testify to your world-leading quality of research and innovation; We are proud to be closely collaborating with @mpi_nat scientists for development of innovative nanosized antibody therapies.